GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » Additional Paid-In Capital

Ablynx NV (XBRU:ABLXS) Additional Paid-In Capital : €425.29 Mil(As of Dec. 2017)


View and export this data going back to . Start your Free Trial

What is Ablynx NV Additional Paid-In Capital?


Ablynx NV's quarterly additional paid-in capital increased from Dec. 2016 (€252.30 Mil) to Jun. 2017 (€253.31 Mil) and increased from Jun. 2017 (€253.31 Mil) to Dec. 2017 (€425.29 Mil).

Ablynx NV's annual additional paid-in capital increased from Dec. 2015 (€187.32 Mil) to Dec. 2016 (€252.30 Mil) and increased from Dec. 2016 (€252.30 Mil) to Dec. 2017 (€425.29 Mil).

Ablynx NV Additional Paid-In Capital Historical Data

The historical data trend for Ablynx NV's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ablynx NV Additional Paid-In Capital Chart

Ablynx NV Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 150.75 183.65 187.32 252.30 425.29

Ablynx NV Semi-Annual Data
Dec07 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 187.32 252.18 252.30 253.31 425.29

Ablynx NV Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Ablynx NV Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Ablynx NV's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Ablynx NV (XBRU:ABLXS) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ablynx NV (XBRU:ABLXS) » Definitions » Additional Paid-In Capital
Comparable Companies
SHSE:603233 HKSE:01530 BLUE SHSE:600161 XSWX:BIOEE BPMC NKTR UTHR XTER:MOR IMMU BBIO ADPT ALLK BOM:532523 CRSP ONCE SZSE:002821 LSE:ABC MRTX RGEN
Traded in Other Exchanges
N/A
Address
Website
http://www.ablynx.com
Ablynx NV is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. It has 45 proprietary and partnered programs in development in various therapeutic areas including inflammation, hematology, immuno-oncology, oncology and respiratory disease. It has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The company generates revenue from research collaboration agreements and from government grants.

Ablynx NV (XBRU:ABLXS) Headlines

No Headlines